Guidelines for Genetic Risk Assessment of Hereditary Breast and Ovarian Cancer: Early Disagreements and Low Utilization
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
BRCA1/2 testing is one of the most well-established genetic tests to predict cancer risk. Guidelines are available to help clinicians determine who will benefit most from testing.
To identify women at high risk of hereditary breast and ovarian cancer and estimate their awareness of and experience with genetic testing for cancer risk.
Analyses of the 2000 and 2005 National Health Interview Surveys.
Women with no personal history of breast or ovarian cancer (n = 35,116).
Risk of hereditary breast or ovarian cancer based on self-reported family history of cancer and national guidelines; self-reported awareness of genetic testing for cancer risk; discussion of genetic testing for cancer risk with a health professional; having undergone genetic testing for breast/ovarian cancer risk.
Using guideline criteria, 0.96% of women were identified as being at high risk of hereditary breast and ovarian cancer. Among high-risk women, 54.04% were aware of genetic testing for cancer risk, 10.39% had discussed genetic testing with a health professional, and 1.41% had undergone testing for breast/ovarian cancer risk. Adjusting for survey year, high-risk women were more likely than average-risk women to have heard of genetic testing for cancer risk (RR, 1.3, 95% CI 1.2-1.4), to have discussed genetic testing with a health professional (RR 5.2, 95% CI 3.6-7.4), and to have undergone genetic testing for breast/ovarian cancer risk (RR 6.8, 95% CI 2.6-18.0).
We find low provision of guideline-recommended advice to women for whom testing may be appropriate and of significant clinical benefit.
- American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):2397–406. CrossRef
- National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian V.1.2007. Fort Washington, PA; 2007.
- US Preventive Services Taskforce. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143(5):355–61.
- Myriad Genetics. Myriad Genetics Awarded Three US Patents And Eight International Patents. Salt Lake City, UT; 2001:News release.
- Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276–92. CrossRef
- Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861–70. CrossRef
- American Cancer Society. Leading sites of new cancer cases and deaths—2008 estimates.; 2008.
- Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2005;143(5):362–79.
- Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30. CrossRef
- Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006;7(3):223–9. CrossRef
- Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60(3):505–14.
- Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20(6):1480–90. CrossRef
- American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996;14(5):1730–6; discussion 1737-40.
- Daly M. NCCN Practice Guidelines: Genetics/Familial High-Risk Cancer Screening. Oncology. 1999;13(11A):161–183.
- American College of Medical Genetics Foundation. Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling and Testing Guidelines. 1999.
- Rosenthal TC, Puck SM. Screening for genetic risk of breast cancer. Am Fam Physician. 1999;59(1):99–104, 106.
- Birkhead GS. Letter to physicians: Genetic Testing for BRCA1 and BRCA2: Information for Health Care Professionals, NYS Dept. of Health, Center for Community Health, August 22, 2007.
- Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6. CrossRef
- McClain MR, Palomaki GE, Hampel H, Westman JA, Haddow JE. Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women. Fam Cancer. 2008.
- Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20(5):1260–8. CrossRef
- Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. Jama. 1999;282(15):1458–65. CrossRef
- Mouchawar J, Valentine Goins K, Somkin C, et al. Guidelines for breast and ovarian cancer genetic counseling referral: adoption and implementation in HMOs. Genet Med. 2003;5(6):444–50.
- Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currivan D, Lerman C. Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med. 2005;20(2):131–8. CrossRef
- Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med. 2003;5(2):70–6. CrossRef
- Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet. 2005;42(10):749–55. CrossRef
- Sabatino SA, McCarthy EP, Phillips RS, Burns RB. Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect Prev. 2007;31(5):375–83. CrossRef
- US task force clarifies who should be screened for BRCA mutations. Reuters Health Medical News 2005 September 6, 2005.
- Bristol N. High-Risk Testing. The Washington Post 2005 September 27, 2005;F02.
- McCullough M. Breast cancer tests get new guidelines. Philadelphia Inquirer 2005 September 7, 2005;A03.
- Rubin R. Genetic predisposition is reason to screen, new guidelines say. USA Today 2005 September 6, 2005;7D.
- Mechanic D, McAlpine DD, Rosenthal M. Are patients’ office visits with physicians getting shorter? N Engl J Med. 2001;344(3):198–204. CrossRef
- Burke W. Taking family history seriously. Ann Intern Med. 2005;143(5):388–9.
- Blumenthal D. Stimulating the Adoption of Health Information Technology. N Engl J Med. 2009.
- Chaudhry B, Wang J, Wu S, et al. Systematic review: impact of health information technology on quality, efficiency, and costs of medical care. Ann Intern Med. 2006;144(10):742–52.
- DesRoches C, Campbell E, Rao S, et al. Electronic health records in ambulatory care - a national survey of physicians. N Engl J Med. 2008;359:50–60. CrossRef
- Emery J, Walton R, Murphy M, et al. Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. Bmj. 2000;321(7252):28–32. CrossRef
- Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. Bmj. 2005;330(7494):765. CrossRef
- Qureshi N, Wilson B, Santaguida P, et al. Collection and use of cancer family history in primary care. Evid Rep Technol Assess (Full Rep). 2007;(159):1–84.
- Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. Jama. 2005;293(14):1729–36. CrossRef
- Gwyn K, Vernon SW, Conoley PM. Intention to pursue genetic testing for breast cancer among women due for screening mammography. Cancer Epidemiol Biomarkers Prev. 2003;12(2):96–102.
- Armstrong K, Weiner J, Weber B, Asch DA. Early adoption of BRCA1/2 testing: who and why. Genet Med. 2003;5(2):92–8.
- Thompson HS, Valdimarsdottir HB, Duteau-Buck C, et al. Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1579–85.
- Hall MA, McEwen JE, Barton JC, et al. Concerns in a primary care population about genetic discrimination by insurers. Genet Med. 2005;7(5):311–6.
- Lerman C, Hughes C, Lemon SJ, et al. What you don’t know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol. 1998;16(5):1650–4.
- Velicer CM, Taplin S. Genetic testing for breast cancer: where are health care providers in the decision process? Genet Med. 2001;3(2):112–9.
- Johnson A. Genetic privacy. Genetics Brief. 2002(4).
- Mulholland WF, Jaeger AS. Genetic privacy and discrimination: a survey of state legislation. Comment. Jurimetrics. 1999;39(3):317–26.
- Guidelines for Genetic Risk Assessment of Hereditary Breast and Ovarian Cancer: Early Disagreements and Low Utilization
Journal of General Internal Medicine
Volume 24, Issue 7 , pp 822-828
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- genetic risk assessment
- breast cancer
- ovarian cancer
- BRCA1/2 testing
- Industry Sectors
- Author Affiliations
- 1. Institute for Health Policy, Massachusetts General Hospital, 50 Staniford St., Suite 901, Boston, MA, 02114, USA
- 2. Harvard/MGH Center for Genomics, Vulnerable Populations and Health Disparities, Boston, MA, USA
- 3. Department of Medicine, Harvard Medical School, Boston, MA, USA
- 4. Division of Population Science, Dana-Farber Cancer Institute, Boston, MA, USA